Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, Norway

Ingebjørg Tronstad,Mari Hoff,Julie Horn,Sigrid Anna Aalberg Vikjord,Vibeke Videm,Jonas Johansson,Tom Ivar Lund Nilsen,Arnulf Langhammer,Tronstad,I.,Hoff,M.,Horn,J.,Vikjord,S. A. A.,Videm,V.,Johansson,J.,Nilsen,T. I. L.,Langhammer,A.
DOI: https://doi.org/10.1136/rmdopen-2023-003919
2024-02-21
RMD Open
Abstract:Objectives Rheumatoid arthritis has been associated with increased fracture risk. New treatments have improved the course of the disease substantially, but it is not clear if this influences fracture risk. We examined if rheumatoid arthritis, overall and according to disease-modifying antirheumatic drugs (DMARDs), is associated with a risk of major osteoporotic fractures. Methods Overall, 92 285 participants in the population-based Nord-Trndelag Health Study (HUNT), Norway were included and linked with hospital records for a validated rheumatoid arthritis diagnosis (n=605), type of DMARD treatment and fracture diagnosis. Participants were followed up until the first major osteoporotic fracture, death, emigration or end of follow-up. Cox regression was used to estimate HRs for fractures among individuals with rheumatoid arthritis, overall and by DMARD treatment, compared with participants without rheumatoid arthritis. Results A total of 9670 fractures were observed during follow-up, of which 88 were among those with rheumatoid arthritis. Compared with the reference group of participants without rheumatoid arthritis, those with the disease had an HR of fracture of 1.41 (95% CI 1.13 to 1.74). The association was largely similar for users of csDMARDs (HR 1.44; 95% CI 1.15 to 1.81), whereas the association for bDMARD users was weaker and less precise (HR 1.19; 95% CI 0.64 to 2.21). Conclusion Participants with rheumatoid arthritis had a 40% higher risk of fracture than participants without the disease. A similar fracture risk was observed for conventional synthetic DMARD use, whereas there was weak evidence that the use of biological DMARDs may be associated with a somewhat lower fracture risk.
rheumatology
What problem does this paper attempt to address?
The paper primarily explores the relationship between the use of different types of disease-modifying antirheumatic drugs (DMARDs) and the risk of major osteoporotic fractures in patients with rheumatoid arthritis (RA). **Research Background:** - Patients with rheumatoid arthritis have a higher risk of fractures. - In recent years, with the application of new treatment options such as biological DMARDs (bDMARDs), the treatment outcomes for rheumatoid arthritis have significantly improved. - However, it is still unclear whether these new therapies can reduce the risk of fractures. **Research Objectives:** - To investigate the overall risk of major osteoporotic fractures in patients with rheumatoid arthritis and according to the type of DMARDs used. - To compare the fracture risk between patients with rheumatoid arthritis and those without. **Research Methods:** - The study is based on data from the Nord-Trøndelag Health Study (HUNT Study) in Norway, including 92,285 participants. - Cox regression analysis was used to assess the fracture risk in patients with rheumatoid arthritis compared to those without, when using different types of DMARDs. **Research Results:** - Patients with rheumatoid arthritis have a 40% higher risk of fractures compared to those without rheumatoid arthritis. - The fracture risk in patients with rheumatoid arthritis using conventional synthetic DMARDs (csDMARDs) is similar to the overall fracture risk in rheumatoid arthritis patients. - Patients with rheumatoid arthritis using biological DMARDs (bDMARDs) have a lower fracture risk, but the evidence is weak. **Conclusion:** - The overall fracture risk in patients with rheumatoid arthritis is higher than in those without rheumatoid arthritis. - The fracture risk in patients using csDMARDs is similar to the overall fracture risk in rheumatoid arthritis patients. - Although the evidence is weak, the use of bDMARDs may be associated with a lower fracture risk, approaching the fracture risk level of non-rheumatoid arthritis patients.